Back to search

Article

Comparative effectiveness of first line pembrolizumab vs. chemotherapy in aNSCLC: A Norwegian Population-Based Cohort Study

2024-10-08

Abstract excerpt

The KEYNOTE-042(1,2) trial showed a benefit of treating patients with non-oncogene addicted advanced NSCLC with PD-L1 tumour proportion score over 50% with Pembrolizumab as monotherapy over platinum doublet chemotherapy. To contextualize these results, we undertake a detailed emulation of the inclusion criteria in Keynote–042 using Norwegian health registry data, and discuss both the clinical context, as well as t...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
34f9417a-87be-536b-9814-793fa5949bce
DOI
10.1101/2024.10.07.24314963
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Comparative effectiveness of first line pembrolizumab vs. chemotherapy in aNSCLC: A Norwegian Population-Based Cohort StudyDOI 10.1101/2024.10.07.24314963
Phase III KEYNOTE-789 Study of Pemetrexed and Platinum With or Without Pembrolizumab for Tyrosine Kinase Inhibitor‒Resistant, EGFR-Mutant, Metastatic Nonsquamous Non-Small Cell Lung Cancer.Semantic proximity
Second-line treatment for advanced NSCLC without actionable mutations: is immunotherapy the 'panacea' for all patients?Semantic proximity
The UK Divide: Does having a Pembrolizumab-Chemotherapy option in head and neck cancer matter? Real-world experience of first-line palliative pembrolizumab monotherapy and pembrolizumab-chemotherapy combination in ScotlandSemantic proximity
Associations of tissue tumor mutational burden and mutational status with clinical outcomes in KEYNOTE-042: pembrolizumab versus chemotherapy for advanced PD-L1-positive NSCLC.Semantic proximity
Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC.Semantic proximity
Brief Report: First-line Pembrolizumab in Metastatic Non-Small Cell Lung Cancer Habouring MET Exon 14 Skipping Mutation and PD-L1 ≥50% (GFPC 01-20 Study).Semantic proximity
Effectiveness and Durable Outcomes with Second-Line Immunotherapy in Advanced NSCLC in Real World Practice in IndiaSemantic proximity
Transportability of patient outcomes from a US clinical trial to real-world populations - a case study using Lung-MAP S1400I (NCT02785952)Semantic proximity
Treatment options beyond immunotherapy in patients with wild-type lung adenocarcinoma: a Delphi consensus.Semantic proximity
First-line pyrotinib in advanced HER2-mutant non-small-cell lung cancer: a patient-centric phase 2 trialSemantic proximity
Real-Life Benefit and Costs of First Line Pembroli-zumab for Advanced NSCLC—A Propensity-Score Matched Case-Control StudySemantic proximity
A retrospective study of first-line therapy and subsequent pyrotinib treatment in advanced lung adenocarcinoma with HER2 mutations.Semantic proximity
Select a neighboring publication to make it the new centre.